KIRKLAND, QC, March 21, 2017 /CNW Telbec/ – Merck Canada Inc. today announced that ZEPATIER® (elbasvir/grazoprevir) will be listed among the drugs covered by Quebec’s health insurance board, the Régie de l’assurance maladie du Québec (RAMQ), as of March 22. Quebec joins other jurisdictions that have approved the product for reimbursement under their public healthcare plans for chronic hepatitis C patients presenting with recognized criteria. Zepatier is indicated for the treatment of chronic infection by genotypes 1, 3 or 4 of the hepatitis C virus in adults.1 The product monograph, including detailed product information and indication, is available online by clicking here.
“This announcement reflects the hepatitis C agreement between Merck and the pan-Canadian Pharmaceutical Alliance (pCPA). We are proud to contribute a solution in the fight against this disease, all the while helping reduce the cost pressure on the healthcare system,” says Chirfi Guindo, President and Managing Director of Merck Canada Inc.
Hepatitis C patients without significant hepatic fibrosis who present with certain comorbidities or specific conditions will be eligible for the treatment, including those who have chronic kidney disease, who are co-infected with the human immunodeficiency virus (HIV) or the hepatitis B virus (HBV), who have undergone an organ transplant or who present with extrahepatic manifestations of the disease.
- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis
- AbbVie’s New Drug Submission is supported by data from its global registrational clinical development program across all major HCV genotypes and in patients with specific treatment challenges
MONTREAL , Feb. 1, 2017 /CNW/ – AbbVie, a global biopharmaceutical company, today announced it has submitted a New Drug Submission (NDS), and received priority review from Health Canada, for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of all major chronic hepatitis C virus (HCV) genotypes.
If approved, G/P may provide a shorter treatment duration for genotypes 1-6 (GT1-6) in patients without cirrhosis, who make up a large portion of HCV patients in Canada , and an additional treatment option to patients with compensated cirrhosis (Child-Pugh A). G/P is also intended to address the unmet medical needs of patients with specific treatment challenges, including those with severe chronic kidney disease (CKD) and those not cured with previous direct acting antiviral (DAA) treatment.
More than 85 percent of Canadian provinces and territories restrict access to new direct-acting antivirals (DAA) for the treatment of the hepatitis C. Courtesy of University of Montreal Hospital Research Centre
The new direct-acting antivirals (DAA) are effective in curing the hepatitis C virus infection, a potentially fatal disease that attacks the liver, but they are expensive–approximately $60,000 per patient. A study conducted by researchers at the University of Montreal Hospital Research Centre (CRCHUM), The Kirby Institute, UNSW Australia, and the Canadian Network on Hepatitis C (CanHepC) shows that nearly everywhere in Canada, provinces and territories impose obstacles to the reimbursement of these medications by the public system because of their cost.
“There are many new direct-acting antivirals, marketed by different pharmaceutical companies. We studied reimbursement practices for simeprevir, sofosbuvir, ledipasvir-sofosbuvir and paritaprevir-ritonavir-ombitasvir plus dasabuvir. We found that 85 to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis,” says Alison Marshall from the Kirby Institute, UNSW Australia, lead author of a study to appear today in CMAJ Open.
HIV and Hepatitis C Community Action Fund will leave many Canadians living with HIV or Hep C out in the cold, with several established service organizations having their funding partially or completely cut.
OTTAWA, Oct. 12, 2016 /CNW/ – Just two weeks after the federal government pledged $804 million to international efforts on AIDS, malaria and tuberculosis at the Global Fund Replenishment Conference, HIV organizations have had their federal funding drastically cut or completely discontinued across Canada. The Public Health Agency of Canada (PHAC) sent out responses from the HIV and Hepatitis C Community Action Fund (CAF) Letter of Intent Process starting on Sept 29, 2016, several months later than originally promised, and the results have been catastrophic for the sector.
Community-based organizations across Canada have been put in a position to fail by a funding process that has been opaque from the beginning. These organizations are now urging PHAC and the federal government to halt the current funding process, and continue status quo funding for one year in order to revisit the process in collaboration with the community. The renewed process would be required to have its goals and criteria posted publically, and be based on consultations with both community organizations and people living with HIV and Hepatitis C. At a minimum, they are asking that PHAC work with the community to determine gaps in funding allocation, and focus on filling those gaps by increasing the value of CAF. Despite previous government commitments, the Federal Initiative, which provides funds to CAF, has not been increased in many years, and, according to a report from PHAC, $13.8 million has remained unspent since 2008.